## Sun Pharmaceutical Industries Ltd.

Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai - 400 063, Maharashtra, INDIA.

Tel.: (91-22) 4324 4324 Fax: (91-22) 4324 4343

Website: www.sunpharma.com CIN: L24230GJ1993PLC019050



## December 27, 2019

National Stock Exchange of India Ltd, Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051. BSE Limited, Market Operations Dept., P. J. Towers, Dalal Street, Mumbai - 400 001. BSE Code- 524715

NSE Code - SUNPHARMA

Dear Sir/Madam,

## Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform that the Hon'ble National Company Law Tribunal, Ahmedabad Bench ("NCLT"), on interpretation ground that an outbound Demerger is not envisaged under Section 234 of Companies Act, 2013, did not allow the Company's petition for the proposed Composite Scheme of Arrangement amongst Sun Pharmaceutical Industries Limited and Sun Pharma (Netherlands) B.V. ("Transferee Company-1") and Sun Pharmaceutical Holdings USA Inc. ("Transferee Company-2") and their respective members and creditors ("Composite Scheme of Arrangement") for transfer of the Specified Investment Undertaking-1 (as defined in the Composite Scheme of Arrangement) and Specified Investment Undertaking-2 (as defined in Composite Scheme of Arrangement) of the Company into Transferee Company-1 and Transferee Company-2 respectively.

The copy of the order pronounced by the Hon'ble NCLT was made available to the Company on 26<sup>th</sup> December, 2019. The Company is reviewing the order in detail and then would decide the future course of action.

The Composite Scheme of Arrangement being an internal restructuring exercise, this order does not impact the consolidated financial statements of the Company.

This is for your information and records.

Thanking you, Yours faithfully,

Før Sun Pharmaceutical Industries Ltd.

Sunil Ajmera

**Company Secretary**